Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Masimo

Apple Watch faces US ban over patent dispute — what you need to know

A patent dispute over the Apple Watch's pulse oximeter tech may lead to an outright ban in the US.

Tom’s Guide

I test headphones for a living and these are the wireless earbuds I'm most excited for in 2023

My favorite wireless earbuds from last year are about to be upstaged by two new models from Denon using the same sound tech for the ultimate personalized listening experience.

Tom’s Guide

Denon PerL earbuds offer Per(sonalized) L(istening) with new proprietary tech

The Denon PerL Pro and Denon PerL use proprietary tech to analyse the user's ear for a tailored listening experience'.

TechRadar

From analysis to the latest developments in health,
read the most diverse news in one place.

Denon's new wireless earbuds are Bose and Sony rivals that can measure your hearing

The new PerL wireless buds challenge the Sony and Bose class-leaders with strong codec support, battery life, ANC and unique tech for a bespoke audio profile

What Hi-Fi?

$1.8 billion Apple Watch lawsuit crumbles as mistrial called

A lawsuit alleging Apple stole trade secrets for future Apple Watch sensors has been called as a mistrial after jurors failed to reach a verdict.

iMore

Shareholder activism's rise comes with more failures

Experts say it's not a sign of an ESG backlash.

Fortune

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

Masimo Corporation (NASDAQ: MASI) delivered adjusted earnings per share (ETF:EPS) of $1.35 in the second quarter of 2022, up 43.6% year over year. The figure surpassed the Zacks Consensus Estimate by 13.5%.

Benzinga

Masimo's Return on Invested Capital Insights

According to Benzinga Pro, during Q1, Masimo (NASDAQ:MASI) earned $46.59 million, a 31.74% increase from the preceding quarter. Masimo's sales decreased to $304.24 million, a 7.12% change since Q4.

Benzinga

7 Analysts Have This to Say About Masimo

Masimo (NASDAQ:MASI) has observed the following analyst ratings within the last quarter:

Benzinga

Masimo Posts Better Than Expected Q1 Earnings Despite 'Unexpected' Supply Chain Issues

Masimo Corp's (NASDAQ:MASI) Q1 revenue increased 1.7% Y/Y (+3.2% on a constant currency basis) to $304.2 million, beating the consensus of $303.83 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 75,700 in Q1 of 2022. The adjusted operating margin remained unchanged at 22.9%. The company reported…

Benzinga

Masimo's Earnings Outlook

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Masimo will report an earnings per share (EPS) of $0.87.

Benzinga

2 Stocks Down 50% Year-to-Date That Are Buys Now

The probability of aggressive interest rate increases by the Fed later this year, and the Ukraine-Russia war, have weighed on the stock market so far this year. However, April has traditionally been one of the best months of the year for stocks. Therefore, we think the recent market dip could…

StockNews.com

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Upgrades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Down by More Than 25%, Grab These 3 Stocks Before They Rebound

Following a disappointing stock market performance since the beginning of the year, progress in peace talks between Russia and Ukraine and an expected steady economic recovery despite the likelihood of more interest rate hikes have improved investor sentiment of late. Therefore, we think it could be wise to bet on…

Benzinga

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Analyst Ratings For Masimo

Analysts have provided the following ratings for Masimo (NASDAQ:MASI) within the last quarter:

Benzinga

Masimo's SedLine Brain Function Monitor Sensor Scores FDA Approval For Pediatric Use

The

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Needham Upgrades Masimo To Buy, With Price Target Of $205

Needham has upgraded Masimo Corp (NASDAQ: MASI) to Buy from Hold with a $205 price target

Benzinga

Masimo Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on Masimo (NASDAQ:MASI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Looking Into Masimo's Return On Capital Employed

According to Benzinga Pro, during Q4, Masimo (NASDAQ:MASI) earned $68.26 million, a 18.15% increase from the preceding quarter. Masimo also posted a total of $327.58 million in sales, a 6.56% increase since Q3.

Benzinga

Masimo Stock Plunges After Q4 Results, Sound United Deal

Masimo Corp's (NASDAQ: MASI)

Benzinga

Masimo: Q4 Earnings Insights

Masimo (NASDAQ:MASI) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Masimo beat estimated earnings by 10.0%, reporting an EPS of $1.21 versus an estimate of $1.1.

Benzinga

A Preview Of Masimo's Earnings

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2022-02-15. Here's what investors need to know before the announcement. Analysts estimate that Masimo will report an earnings per share (EPS) of $1.10.

Benzinga

Ominous Death Cross Forms On Masimo's Chart

If history is any guide, there may be trouble ahead for shares of Masimo (NASDAQ:MASI). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1 2 3 4 5

People

Joe Kiani

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.